These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 20173157)

  • 1. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer.
    Bellomi M; Rizzo S; Travaini LL; Bazzi L; Trifirò G; Zampino MG; Radice D; Paganelli G
    Radiol Med; 2007 Aug; 112(5):681-90. PubMed ID: 17657420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
    Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
    Granados Rangel O; Estrada G; Altamirano J
    Gac Med Mex; 2014; 150(6):509-17. PubMed ID: 25375281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
    Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
    AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
    Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
    Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
    Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer.
    Sarikaya I; Povoski SP; Al-Saif OH; Kocak E; Bloomston M; Marsh S; Cao Z; Murrey DA; Zhang J; Hall NC; Knopp MV; Martin EW
    World J Surg Oncol; 2007 Jul; 5():80. PubMed ID: 17634125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M; Yener C; Karabulut E
    Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.